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Abstract
Objective The objective of the study is to compare the
diagnostic value of regional sampling of the cerebral
metabolic rate of glucose metabolism (MRglc) using
[18F]-fluoro-2-deoxyglucose ([18F]FDG)-positron emis-
sion tomography (PET) and amyloid-beta pathology using
Pittsburgh Compound-B ([11C]PIB)-PET in the evaluation
of patients with Alzheimer’s disease (AD) and mild
cognitive impairment (MCI) compared to normal elderly
(NL).
Materials and methods AD patients, 7 NL, 13 MCI, and
17, received clinical, neuropsychological, magnetic reso-
nance imaging (MRI), FDG, and PIB-PET exams. Para-
metric images of PIB uptake and MRglc were sampled
using automated regions-of-interest (ROI).
Results AD showed global MRglc reductions, and MCI
showed reduced hippocampus (HIP) and inferior parietal
lobe (IP) MRglc compared to NL. On PIB, AD patients
showed significantly increased uptake in the middle frontal
gyrus (MFG), posterior cingulate cortex (PCC), and IP (ps<
0.05). PIB uptake in MCI subjects was either AD or NL-like.
HIP MRglc and MFG PIB uptake were the best discrim-
inators of NL from MCI and NL from AD. These two best
measures showed high diagnostic agreement for AD (94%)
and poor agreement for MCI (54%). For the NL vs. MCI
discrimination, combining the two best measures increased
the accuracy for PIB (75%) and for FDG (85%) to 90%.
Conclusion For AD, the pattern of regional involvement for
FDG and PIB differ, but both techniques show high
diagnostic accuracy and 94% case by case agreement. In
the classification of NL and MCI, FDG is superior to PIB,
but there is only 54% agreement at a case level. Combining
the two modalities improves the diagnostic accuracy for
MCI.
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Introduction
Alzheimer’s disease (AD) is an age-related neurodegener-
ative disorder that results in progressive loss of cognitive
function. AD is characterized by the accumulation of the
amyloid-beta (Aβ) peptide into amyloid plaques in the
extracellular brain parenchyma and by intraneuronal neu-
rofibrillary tangles caused by the abnormal phosphorylation
of the tau protein [1]. Amyloid deposits and tangles are
necessary for the post mortem diagnosis of AD [2].
Imaging techniques, such as positron emission tomogra-
phy (PET), have long been used to visualize brain damage
in AD and in mild cognitive impairment (MCI), often a
prodrome to AD [3]. There is increasing evidence that
reductions in the cerebral metabolic rate of glucose
(MRglc), as measured with PET using [18F]-fluoro-2-
deoxyglucose (FDG) as the tracer, can be consistently
detected in MCI patients compared to age-matched normal
controls, mostly involving the parieto-temporal, posterior
cingulate, and medial temporal cortices [4–7]. MRglc is an
index of synaptic functioning and density [8], but hypo-
metabolism is not specific to AD, as it is observed in other
neurodegenerative disorders (see [9] for review). Moreover,
MCI is a clinical diagnosis in need of confirmatory
biological evidence for disease. A recent large population-
based study showed up to 40% of patients with MCI who
were subsequently diagnosed as cognitively normal [10].
The PET tracer, N-methyl[11C]2- (4'-methylamino-
phenyl)-6-hydroxy-benzothiazole, better known as Pitts-
burgh Compound-B (PIB), was used to detect amyloid
deposition in vivo. Prior PIB-PET studies demonstrate
quantitative increases in PIB uptake, reflecting greater
amyloid burden, in AD and MCI patients compared to
controls [11–14]. In AD, PIB uptake is particularly evident
in the frontal, parieto-temporal, and posterior cingulate
cortices, in keeping with the known distribution of amyloid
plaques [15–17]. However, recent data also show that many
MCI patients fall in between AD and control values for PIB
binding, and some clinically normal subjects also show an
elevated PIB uptake [13, 14]. These findings are also
consistent with clinico-pathology studies showing that
typical amyloid lesions are found in both demented and
non-demented individuals [18, 19]. These results suggest
that the presence of amyloid may be necessary, though not
sufficient for the symptoms consistent with the MCI stage
of AD. The present study used a newly developed
automated region of interest technique to compare the
diagnostic value and concordance of FDG-PET and PIB-
PET in AD and MCI.
Materials and methods
Subjects
Thirty-seven subjects, including: 17 AD and 13 MCI
patients and 7 normal elderly (NL) patients, were examined
at the University of Turku, Finland. All subjects underwent
thorough clinical examinations including a medical history
corroborated by a close informant, neurological and
neuropsychological examinations, routine blood analysis,
and magnetic resonance imaging (MRI). The AD patients
were diagnosed according to the National Institute of
Neurological and Communication Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
(NINDS-ADRDA) [20] and DSM-IV criteria [21]b ya n
experienced neurologist. Dementia severity was evaluated
with the Mini-Mental State Examination (MMSE) [22]. All
AD patients had progressive impairment of memory and
impairment in at least one additional field of cognitive
function.
All 13 MCI patients met the criteria for “amnestic MCI”
[23]. The NL controls were healthy volunteers who
contacted Turku PET Centre after announcement in news-
paper or in public lectures concerning needed participation in
memory studies. None of the controls reported or revealed
on examination any neurological or psychiatric disease, prior
head trauma, sensory impairment, or subjective cognitive
complaints. The PET scans were used for the research
evaluations and were not used for selection purposes. The
study was approved by the Ethics Committee of Southwest
Finland Health Care District.
Brain imaging
PET imaging All subjects underwent two PET scans, one
with PIB and one with FDG on a GE Advance PET scanner
(GE Medical Systems, Milwaukee, WI, USA) in the three-
dimensional scanning mode (septa retracted), yielding 35
slices with 4.25 mm thickness that covered the whole brain.
The spatial resolution (full width at half-maximum) of the
camera is 4.3 mm transaxially and 4.3 mm axially. Laser
light beams were used for head positioning, with alignment
determined by orbitomeatal and sagittal lines. Before the
injection of either radiotracer, an 8-min transmission scan
with
68Ge rod sources was done for attenuation correction.
All imaging data were reconstructed into a 128 × 128
matrix using a transaxial Hanning filter with a 4.6-mm
cutoff, and an axial ramp filter with an 8.5-mm cutoff.
PIB-PET PIB-PET scans were acquired during a 90-min
dynamic PET acquisition. [11C]PIB was injected into an
antecubital vein as a bolus, with a mean dose of 382±
103 MBq, and flushed with saline. The frame sequence of
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frames, three 3-min frames, ten 5-min frames, and two 10-
min frames. PIB-PET parametric images were obtained
using the noninvasive Logan graphical analysis [24] using
the 60- to 90-min scans and the cerebellum as the reference
region to estimate the PIB distribution volume ratios
(DVR). This procedure has proved to be reliable and valid
for PIB-PET studies in AD [25].
FDG-PET FDG-PET scans were acquired with a 55-min
dynamic PET acquisition. During the uptake period,
arterialized venous blood was sampled every 20 s for the
first 3 min, every 1 min from 3 to 5 min, every 2.5 min
from 5 to 10 min, every 5 min from 10 to 35 min, and every
10 min from 35 to 55 min. The frame sequence of the FDG
scan consisted of four 30-s frame, three 1-min frames, and
ten 5-min frames. A Patlak plot was used to estimate the
brain MRglc [26].
MRI MRIwasperformedwithaPhilipsGyroscanIntera1.5T
CV Nova Dual scanner (Philips, the Netherlands). MRI
included axial spin echo T2-weighted images (TR=
4488 ms; TE=100 ms, slice thickness=6 mm, matrix=512×
512), and 3D T1-weighted images (TR=25 ms, TE=5 ms,
slice thickness=1 mm, matrix=512×512).
Image analysis
All image processing and data analyses were performed at
NYU blind to clinical diagnoses. MRI and PET scans were
transferred to a Sun Sparc work-station (Sun Microsystems,
Mountain View, CA, USA) where PIB- and FDG-PET scans
were each co-registered with the corresponding MRI using a
three-dimensional method based on minimizing the variance
of the signal ratios [27], as implemented in the Multimodal
Image Data Analysis System package (MIDAS, version 1.6)
[28]. The implementation calls for a preliminary spatial
alignment using intrinsic anatomical landmarks.
An MRI-based automated region of interest (ROI)
technique was used to sample each individual’s FDG and
PIB images. The technique was validated by a manual ROI
technique that is described in detail in the Appendix.T h e
template ROI was first developed on seven MRI scans and
then transferred to a co-registered MNI PET template. All
PET scans were normalized to the PET template by a high-
order polynomial transformation [29]. With spatial normal-
ization parameters saved, an inverse transformation is
applied to morph the ROIs back to the original FDG-PET.
The standard FDG-ROI’s are then transferred to the PIB scan
in real space through the co-registration. ROI positioning
was verified on the MRI, but no positioning adjustments
were made in this project. To maximize gray matter (GM)
sampling, a probabilistic grey matter template image was
derived from SPM [30] and added as template ROI (see
Appendix). Nine MRI and FDG-PET validated automated
ROIs were studied including: anterior putamen (APu), grey
matter (GM), hippocampus (HIP), inferior parietal lobe (IP),
middle frontal gyrus (MFG), posterior cingulate cortex
(PCC), cerebellum (C), superior temporal gyrus (STG),
thalamus (TH).
The posterior lobe of the cerebellar cortex was used as
the reference region for both PIB and FDG analyses. The
cerebellum is minimally affected by either MRglc reduc-
tions [4, 31] or by amyloid pathology [32, 33]i nA D .
Statistical analysis
The general linear model (GLM) univariate analysis of
variance (ANOVA), with Tukey post hoc tests, was used to
examine demographic, clinical, FDG MRglc, and PIB
uptake measures across the three clinical groups. All
significant results were confirmed using the nonparametric
Mann–Whitney test with Bonferroni correction for multiple
comparisons. Categorical demographic variables were
examined with Chi-Square analysis and confirmed with
Fisher’s exact tests. PIB DVR is expressed as a ratio to
cerebellar uptake. MRglc measures were adjusted for
cerebellar MRglc as a covariate in the GLM. The bilateral
regions showing the largest group effects (as determined by
MANOVA) were examined with logistic regressions and
ROC curves to assess their diagnostic accuracy in classify-
ing the NL, MCI, and AD groups. The ROC curve was also
used to determine optimal cutoff value for MRglc and PIB
DVR in separating NL, MCI, and AD. Results were
considered significant at p<0.05. All analyses were done
using SPSS 12.0 (SPSS, Chicago, IL 2004, USA).
Results
Clinical data
The NL, MCI, and AD groups were comparable for age,
gender, and education (see Table 1). The MMSE was
significantly lower in AD subjects than in NL and MCI
(p<.05), but did not differ between MCI and NL. MMSE
scores in the AD group ranged from 17 to 27, which
corresponds to mild to moderate dementia.
Group differences
FDG-PET Of the nine regions tested, five regions showed
significant post hoc differences between the NL and AD
groups (Fig. 1, Table 2), with the AD group showing
Eur J Nucl Med Mol Imaging (2008) 35:2169–2181 2171reduced MRglc compared to NL in the HIP (43%), PCC
(21%), IP (18%), MFG (13%), (ps<.05). Significant MRglc
reductions in MCI compared to NL were found for the HIP
(16%) and IP (13%), and in AD compared to MCI
reductions, which were only found in the HIP (23%;
p’s<.05). For all group comparisons, the HIP MRglc was
the most significant group discriminator (F[2,34]=33.9,
p<.001). No cerebellar differences were observed for any
group comparisons.
PIB-PET AD patients showed significantly higher PIB
uptake compared to both NL and MCI groups (F[2,34]=
14.6, p<.005), respectively, in the GM, MFG, PCC, IP,
STG (Fig. 2,T a b l e3). The MFG was the region showing
the highest PIB uptake (F[2,34]=14.6, p<.001), which was
66% higher in AD compared to NL (p=.0001), and 29%
higher compared to MCI (p=.004). There is no significant
differences found between NL and MCI; however, the
A P ur e g i o ns h o w e dat r e n df o rh i g h e rP I Bu p t a k ei nM C I
(p=.06). No cerebellar differences were observed for any
group comparisons.
PIB-FDG associations Negative correlations between the
FDGandPIBmodalitieswereobservedwhenthethreegroups
were combined: IP (r=−0.43, p=.001), STG (r=−0.41,
p=.001), and PCC (r=−0.40, p=.001). However, no
significant intraregional correlations were observed within
any of the three diagnostic groups.
As shown in Fig. 3, the FDG-PET and PIB-PET data
show different regional patterns of involvement in AD
compared with NL. The most significantly affected region
on FDG was the hippocampus and the middle frontal gyrus
on PIB (Fig. 4).
Diagnostic models
Logistic regression models were used to examine regional
uptake and FDG-MRglc as predictors of group member-
ship. Diagnostic classification accuracy, sensitivity (SS),
and specificity (SP) are found in Table 4.
AD vs. NL HIP MRglc yielded an accuracy of 92% (Χ
2
[1]=
21.8, p<.001, SS=100, SP=88). MFG PIB uptake distin-
guished AD from NL with 96% accuracy (Χ
2
[1]=29.0,
p<.001, SS=94, SP=100). Using a PIB-DVR cutoff of 1.4,
three regions including the MFG, PCC, and IP each
separated 16 out of 17 AD and 7 out of 7 NL with 94%
Table 1 Subjects’ characteristics
Subjects NL MCI AD
N 71 31 7
Age in years [range] 69.1 (5.4)
[59–74]
71.6 (4.6)
[64-80]
72 (4.7)
[59-79]
Education (years) 9.9 (2.9) 10.8 (3.8) 9.7 (4.0)
Mini Mental State
Exam [range]
28.9 (0.9)
[28–30]
27.6 ( 1.4)
[25–29]
23.6 ( 2.9) *,**
[17–27]
Gender (% female) 71% 31% 53%
Values are mean (SD).
*Significantly different from NL, p<0.05
**Significantly different from MCI, p<0.05
Fig. 1 Scatter plots showing
regional cerebellar adjusted
MRglc (umol/100 g/min) for the
HIP, MFG, IP, and PPC in NL,
MCI, and AD groups. The hor-
izontal lines show the group
means
Table 2 FDG-PET MRglc data by diagnostic group
Region NL MCI AD
APu 28.4 (1.31) 26.7 (0.98) 26.1 (0.86)
GM 21.6 (0.63) 19.7 (0.47) 19.2 (0.41)*
HIP 20.4 (0.79) 17.6 (0.59)* 14.3 (0.52)*,**
IP 23.7 (0.87) 21.0 (0.65)* 20.1 (0.57)*
MFG 26.0 (0.99) 23.2 (0.75) 23.0 (0.65)*
PCC 25.8 (0.98) 23.0 (0.74) 21.4 (0.64)*
STG 22.2 (0.96) 20.0 (0.72) 19.8 (0.63)
TH 27.9 (1.42) 26.9 (1.06) 25.7 (0.93)
Values are mean (SD) of covariate adjusted values.
APu Anterior putamen, GM gray matter, HIP hippocampus, IP inferior
parietal lobule, MFG middle frontal gyrus, PCC posterior cingulate
cortex, STG superior temporal gyrus, TH thalamus
*Significantly different from NL, p<0.05
**Significantly different from MCI, p<0.05
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96%. The one erroneously classified as AD subject had the
PIB-DVR lower than 1.4 in all three regions (Fig. 2).
Comparing PIB-MFG and FDG-HIP, there was high
diagnostic agreement for the classification of AD (94%)
and NL (86%) subjects.
MCI vs. NL The accuracy for the HIP MRglc in distin-
guishing MCI from NL was 85% (Χ
2
[1]=9.2, p<.01, SS=
85, SP=86), and for MFG PIB uptake, the accuracy was
75% (Χ
2
[1]=7.2, p<.01, SS=62, SP=100). Thus, about
60% of the MCI subjects showed an AD-like DVR>1.4;
see Fig. 5). Comparing PIB-MFG and FDG-HIP for the
classification of MCI showed, there was poor agreement
(54%). Only 7 out of 13 MCI cases showed both high PIB
binding and low MRglc. Combining the MFG PIB and
HIP-FDG measures improved the classification of NL and
MCI to 90% (increment Χ
2
[1]=4, p<.05, SS=92, SP=86).
In an effort to relate these MCI data to the clinical findings,
we examined the association between MFG PIB uptake and
MMSE scores. All lower MMSE 25-27 scoring MCI
patients were AD-like (PIB DVR>1.4) and all NL-like
MCI (PIB DVR<1.4) had MMSE scores >28 (see Fig. 3,
t=2.7[1,11], p<0.05). There were no regional MRglc differ-
ences between the high and low MMSE MCI group. As
mentioned above, the MCI patients typically showed low
HIP MRglc. Graphic depiction of the MFG-PIB and HIP-
FDG relationships by MMSE score is found in Fig. 5.
These data show that all lower MMSE 25–27 scores, MCI
patients are in the high PIB binding and low MRglc
quartile. For the low MMSE group, there was 100%
agreement between PIB and FDG, as opposed to 33% for
high MMSE group.
AD vs. MCI MFG PIB uptake yielded an overall accuracy
of 77% in distinguishing AD from MCI (Χ
2
[1]=8.9, p<.01).
HIP MRglc yielded an accuracy of 80% (Χ
2
[1]=11.6,
p<.01). The combination of MFG PIB uptake and HIP
MRglc improved the classification of AD and MCI to 83%
(increment Χ
2
[1]=4.1, p<.01, SS=82, SP=85).
Discussion
The uptake of the beta amyloid PET tracer [11C]PIB was
significantly increased in AD compared to age-matched
healthy controls. This effect was found bilaterally in the
middle frontal gyrus, anterior putamen, inferior parietal
Fig. 2 Scatter plots showing
regional PIB binding from the
ROI analysis in the hippocam-
pus, MFG, IP, and PPC in
subjects with NL, MCI, and AD.
The small horizontal lines show
the groups mean values. The
large horizontal line shows for
reference purposes the DVR set
to 1.4
Table 3 PIB-PET DVR data by diagnostic group
Region NL MCI MCI:NL ratio AD AD:NL ratio
APu 1.21 (0.11) 1.67 (0.50) 1.38 1.99 (0.42)* 1.64
GM 1.12 (0.09) 1.29 (0.22) 1.15 1.54 (0.24)*,** 1.38
HIP 1.03 (0.11) 1.02 (0.11) 0.99 1.08 (0.16) 1.05
IP 1.19 (0.12) 1.48 (0.35) 1.24 1.82 (0.35)*,** 1.53
MFG 1.16 (0.09) 1.50 (0.36) 1.29 1.92 (0.36)*,** 1.66
PCC 1.26 (0.14) 1.58 (0.38) 1.25 1.93 (0.39)*,** 1.53
STG 1.15 (0.13) 1.36 (0.32) 1.18 1.67 (0.30)*,** 1.45
TH 1.38 (0.12) 1.44 (0.30) 1.04 1.64 (0.23) 1.19
*AD Significantly different from NL, p<0.05
**AD Significantly different from MCI, p<0.05
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pattern of PIB uptake was found involving the middle
frontal gyrus and inferior parietal lobule. This observation
is also consistent with findings reported in previous studies
[14, 34]. The FDG-PET data demonstrated that AD patients
show a pattern of bilateral MRglc reductions in the
hippocampus, posterior cingulate, inferior parietal, and
frontal cortices, while MCI patients presented with hypo-
metabolism most consistently in the hippocampus and in
the parietal cortex. These findings are also consistent with
prior FDG-PET studies [6, 7, 37, 38, 39, 40].
The MFG PIB uptake separated 16 out of 17 AD patients
from NL control with 100% specificity and 96% sensitivity.
This contributes to the view that [11C]PIB-PET will have
utility as a diagnostic marker for AD. Only one 73-year-old
male AD patient [Global Deterioration Scale (GDS) 5,
MMSE 19] showed low PIB retention (DVR=1.29). The
finding of occasional “PIB negative” AD patients has been
previously reported [14, 35], and the reason is unclear. Such
findings require post mortem clarification. On the other
hand, the FDG-PET scan of this AD patient showed
evidence for a neurodegenerative disorder consistent with
AD, as reflected in the bilateral MRglc reductions in the
parieto-temporal posterior cingulate cortices and medial
temporal lobes. While direct diagnostic comparison be-
tween PIB and FDG imaging is uncommon, a previous
study [36] reported PIB-PET to be superior to FDG-PET in
classifying AD from NL. Unlike our study, this paper only
studied neocortical regions and not hippocampus, which we
found most discriminative on FDG-PET. Our study shows
that the best regions for FDG-PET (hippocampus) and PIB-
PET (middle frontal gyrus) have high diagnostic agreement
for AD (94%) and NL (86%) indicating approximately
equal value in the clinical diagnosis of AD. The combina-
tion of two PET modalities did not improve the diagnostic
discrimination between AD and NL. That there was no
appreciable increase in the classifications of AD and NL, is
attributable to the very high accuracy each modality
achieved on its own.
We found that several PIB regions were found to
discriminate between MCI and NL with accuracies in the
60–75% range compared with FDG regions that performed
in the 70–85% range. FDG-PET appears to be superior to
PIB-PET in the classification of NL and MCI. Moreover,
the diagnostic agreement between the two PET modalities
for MCI was only 54%; four MCI subjects with MRglc
reductions showed low PIB retention and one MCI subject
with normal MRglc showed high PIB retention. With MCI
subjects separated into high PIB uptake (AD-like) and low
PIB uptake (NL-like) groups (Fig. 5), we found that the
MCI subjects with high MMSE scores (≧28) have NL-like
PIB scans and MCI subjects with low MMSE scores have
AD-like PIB scans. Moreover, elevated PIB and low MRglc
was found in 100% of low performing MCI compared with
only 33% agreement for the high performing MCI. These
data suggest that low performing MCI subjects with PIB
positive scans are at increased risk for dementia. Overall,
the data show that the combination of two PET modalities
improves the diagnostic discrimination between MCI and
NL. Longitudinal studies are needed to clarify the utility of
the PIB and FDG-PET imaging in assessing risk for AD.
Our results comparing MCI and AD showed different
patterns of regional involvement depending on the PET
imaging modality. We observed that the mean PIB values
for several regions differed between MCI and AD and that
their diagnostic classifications were significant. Consistent
diagnostic PIB effects (~70% accuracy) were found in the
middle frontal gyrus, posterior cingulate, inferior parietal
Fig. 3 PIB and FDG-PET scans from two representative subjects: a A
71-year-old male AD subject, GDS 5, MMSE 19; b a 65-year-old
male NL subject, GDS 1, MMSE 29. Top row: PIB-PET images;
bottom row: co-registered FDG-PET images. PET scans are displayed
in the axial plane, from the top to the bottom of the brain, at the level
of the centrum-semiovale (left), basal ganglia (center), and medial
temporal lobe (right)
2174 Eur J Nucl Med Mol Imaging (2008) 35:2169–2181lobule, and the superior temporal gyrus. For FDG, the
hippocampus, the only region that showed a mean MRglc
reduction in AD relative to MCI also showed the only
significant diagnostic effects (~80%). This result of
modality-specific informative regions underlies our second
example where the combination of the two PET techniques
yields complementary information in the detection of
pathology. In our study, the combination of the two PET
modalities improved the diagnostic discrimination between
MCI and AD and between MCI and NL.
We did not observe an inverse relationship between the
regional PIB and FDG data in AD as reported by others
[14, 35]. This discrepancy may be in part due to the
statistical designs used to study the data. Klunk et al
Table 4 Diagnosis classification accuracy, sensitivity, and specificity (%) of PIB-PET and FDG-PET
Region NL vs. AD NL vs. MCI MCI vs. AD
A SS SP A SS SP A SS SP
PIB-PET
APu 70 62 86 –––
HIP 96 94 100 ––– –––
IP ––– 70 54 100 73 94 54
MFG 96 94 100 75 62 100 70 94 62
PCC 96 94 100 60 54 71 73 94 54
STG 88 94 71 ––– 67 65 69
FDG-PET
APu ––– ––– –––
HIP 92 88 100 85 85 86 80 76 85
IP 83 88 71 75 77 71 –––
MFG 79 76 86 80 92 57 –––
PCC 88 88 86 70 62 86 –––
STG 79 82 71 70 69 71 –––
The most significant region was labeled by bold font and “–” stand for nonsignificant.
A Accuracy, SS sensitivity, SP specificity, APu anterior putamen, HIP hippocampus, MFG middle frontal gyrus, IP inferior parietal lobe, PCC
posterior cingulate cortex, STG superior temporal gyrus
Fig. 4 Mean MCI and AD
Z-scores relative to NL. The
most significantly affected re-
gion for FDG is the hippocam-
pus and for PIB, frontal
neo-cortex
Eur J Nucl Med Mol Imaging (2008) 35:2169–2181 2175demonstrated a significant correlation in the inferior parietal
cortex in a combined group of AD and NL patients.
However, they observed that this effect did not remain
significant when only AD patients were studied. [14].
While Edison et al. showed lower CMRglc values
correlated with higher PIB uptake ratios in temporal
(p=.05, r=−0.58) and parietal lobes (p=.041, r=−0.60) in
12 AD subjects, they also observed a high frontal amyloid
load in the face of spared glucose metabolism. These
preliminary results suggest that the weak inverse correla-
tions observed may be due to either group diagnostic effects
or to different regional metabolic vulnerability due to the
complex neuropathology of AD. Overall, it appears that
amyloid plaques may not be directly responsible for
neuronal dysfunction in AD.
In the present study, we describe the continued develop-
ment of an automated ROI technique custom-tailored for
FDG and PIB-PET images (see Appendix for technical
details). Several automated tools are used in neuroimaging
studies to examine and sample brain regions. Foremost,
voxel-based analysis (VBA) techniques with statistical
parametric mapping procedures provide examination of
statistical effects through the whole-brain on a voxel-by-
voxel basis [41, 42]. The basic procedure in VBA involves
the spatial normalization and smoothing of each individual
PET scan to a spatially standardized brain reference image
(i.e., the “template” image) in the stereotactic space, thus
enabling automated voxel-by-voxel assessment of statistical
effects [41, 42]. However, the MRI-guided ROI technique
remains the gold standard for PET sampling, especially in
aging and degenerative diseases, because of its superior
anatomical precision. On the other hand, the conventional
manual ROI sampling is time consuming and operator
dependent, and PET images are often acquired without a
corresponding 3D research MRI. To examine large data sets
with reasonable anatomical precision, we describe the
development of an automated ROI technique custom-
tailored for sampling the cortical and medial temporal lobe
regions affected in AD on FDG and PIB-PET images.
These procedures were validated against the gold-standard
manual ROI determined on the co-registered MRI scans.
The automated ROI data in this project showed high
anatomical precision as assessed on the MRI scans and
high agreement with respect to the manual MRglc sampling
(r’s>0.90) and manual PIB sampling (r’s>0.90; detail was
described in Appendix). In the present study, the anatomical
accuracy of the automated ROIs was excellent in all
subjects, and positional adjustments were not made.
Our automated method offers several advantages com-
pared to other commonly used image analysis tools. First,
the ROIs are applied via inverse transformation to the
original image instead of the spatially normalized image,
thus preserving the anatomical shape of the region and
avoiding possible sampling errors. Moreover, the anatom-
ical precision of the ROIs can be directly examined on the
MRI and PET scans in the original space, and manual
adjustments can be made if necessary. Furthermore, we
applied a sampling strategy to optimize gray matter
sampling, which minimizes partial volume effects and
nonspecific white matter binding, which may confound
detection of regional changes on PIB-PET.
There are some limitations in this study. First, the
recruitment of patients at a university-based unit limits the
generalization of the results. Second, we used a probabilis-
tic gray matter sampling technique instead of the traditional
MRI-based atrophy correction. While our tests suggest
comparability between the two techniques, there remains
the possibility that it may not remove partial volume effect
thoroughly. Third, this study relied on cross-sectional data
where longitudinal follow-up studies are needed to deter-
mine the predictive accuracy of PIB-PET and FDG-PET in
the MCI progression to AD.
Conclusion
We developed and applied an automated image analysis
system for the regional sampling of PIB and FDG PET
scans in a cross-sectional study of normal elderly, MCI, and
AD. We observed widespread cortical amyloid deposition
and widespread reductions in brain glucose metabolism in
AD patients that were of equivalent high value in diagnosis.
For MCI, the regional patterns were less prominent. For
Fig. 5 Scatter plots showing the combined use of PIB of MFG and
FDG of HIP on the classification of the NL, MCI, and AD groups
2176 Eur J Nucl Med Mol Imaging (2008) 35:2169–2181both the AD and the MCI groups, the diagnostically most
useful PIB region was the middle frontal gyrus, and the
most useful MRglc reductions were found in the hippo-
campus. For MCI, the two modalities were diagnostically
inconsistent, and this contributed to their combined added
value. Little evidence was found for an inverse relationship
between regional PIB uptake and reduced MRglc. Longi-
tudinal studies are needed to clarify the early and relative
predictive utility of PIB and FDG-PET imaging in assessing
the risk for progressive cognitive decline among MCI
patients and for assessing probable AD patients without
significant PIB uptake.
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Appendix
Summary
We previously developed and validated an automated ROI
procedure for the hippocampus [1]. Below, we describe the
development of an automated cortical regions-of-interest
(ROI) technique custom-tailored for FDG and PIB-PET
images in NL and AD subjects. The template ROI was first
developed on seven MRI scans and then transferred to a co-
registered MNI PET template. The technique was validated
against the gold-standard manual ROI approach and shows
high anatomical precision as assessed on MRI scans and
high sampling accuracy with respect to the manual MRglc
sampling. This technique enables one to regionally sample
individual brain PET scans in an automated fashion with
high anatomical precision without an MRI scan. In brief, an
individual subject’s FDG-PET image is first spatially
normalized to the standard FDG-PET template by a high-
order polynomial transformation [2]. The reverse of this
transformation is then applied to the ROIs on the template
to map them back to sample the original FDG-PET image
[3]. While the technique we developed does not require an
MRI, with the availability of a co-registered MRI, the
positional accuracy of the sample site can be individually
verified. This program was implemented in the NYU
MIDAS image analysis software package [3].
Development of anatomy-validated standardized regions
of interest
ROIs were manually drawn on the Montreal Neurological
Institute (MNI) single-subject MRI template [4], based on
specific anatomical landmarks (such as brain fissures and
sulci), using published protocols with known intra-rater
reliability higher than 90% [5, 6, 7]. The ROIs were then
transferred to six spatially normalized MRI scans [three
elderly normal (NL) and three Alzheimer disease (AD)
patients]. The mean positions of the boundary sulci from
the seven subjects were determined and used to determine
the final “probabilistic” ROI boundaries [8]. This has the
effect of reducing the anatomical variation of the template
ROIs [9].
The MNI single-subject MRI template image was
resampled on a 105×126×91 matrix with an isotropic
voxel size of 1.5×1.5×1.5 mm. The template ROIs defined
included: prefrontal cortex (PF), middle frontal gyrus
(MFG), superior temporal gyrus (STG), inferior parietal
lobule (IP), posterior cingulate cortex (PCC), occipital lobe
(OL), cerebellum (C) (see Fig. 1). The hippocampus (HIP),
thalamus (T), and anterior putamen (APu) were sampled
using the previously published Hipmask technique [1].
To maximize grey matter (GM) sampling, each ROI was
further accommodated in size according to a priori grey
matter template image [10]. This a priori GM image is a
probabilistic image of MRI-based GM distribution in the
general population [10], with intensity in each voxel
representing the probability that the voxel includes GM.
On this probabilistic GM image, only voxels with GM
probability >90% were retained, and each ROI was
restricted in size to match the new defined probabilistic
boundaries. Furthermore, to limit partial volume CSF
effects at the gray matter ROI boundaries, each ROI was
eroded by 2 pixels (3.0 mm) in all directions.
Consequently, the template ROIs were used to sample
MRglc and PIB for all subjects by applying an inverse
transformation that morphs all ROIs back to the original
PET images while preserving the anatomical shape of the
region.
Sampling the PET Scans
PET scans were normalized to the MNI PET template
space to obtain the transformation parameters. This
protocol avoids the necessity of having to have MRI
scans to undertake an automated analysis. Because the
alternative normalization of an individual MRI to an MRI
template, with the subsequent transferring normalization
parameters to a corresponding PET image, may provide a
higher spatial accuracy than normalization of a PET image
to a PET template image, the two normalization methods
were tested. The ROI template program was used to
compare the MRI vs. PET normalizations. We observed
high correlations between the two normalization methods:
for FDG-PET, the r’s ranged from 0.85 (HIP) to 0.98 (IP)
(p’s<.001), and for PIB-PET the r’s ranged from 0.87
( S T G )t o0 . 9 2( I P )( p’s<.001).
Eur J Nucl Med Mol Imaging (2008) 35:2169–2181 2177Figure 6
Validating the ROI Template
Methods The anatomical precision and sampling accuracy
of the technique was verified on the co-registered MRI and
FDG-PET scans of 49 subjects, including 34 NL elderly
recruited at NYU and 15 AD patients recruited at th-e
University of Turku, Finland. A validation study was also
conducted with the PIB-PET scans of the AD patients.
Subjects’ characteristics are found in Supplemental Table 5.
All subjects received an extensive screening and diagnostic
battery that consisted of medical, neurological, psychiatric,
neuropsychological, and MRI examinations. The NL
selected for study had MMSE [11] scores≥28 and Global
Deterioration Scale (GDS) [12] scores of 1 or 2. The AD
patients were diagnosed according to the National Institute
of Neurological and Communication Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
(NINDS-ADRDA) [13] and DSM-IV criteria [14].
The NYU high-resolution MRI were acquired on a 1.5-T
Signa magnet (General Electric, Milwaukee, WI) with a
standard whole brain 3D T1-weighted protocol [Radio
Fig. 6 a Template ROIs in
FDG-PET template space.
b Automated ROIs were trans-
ferred from A to the original
FDG-PET of a 71-year-old,
male, AD patient. Note how the
ROI’s follow the patient rotation
and tilting in b relative to the
template image. ROIs: 1 Middle
frontal gyrus (MFG), 2 inferior
parietal lobule (IP), 3 posterior
cingulate cortex (PCC), 4 oc-
cipital lobe (OL), 5 prefrontal
cortex (PF), 6 superior temporal
gyrus (STG), 7 anterior putamen
(APu), 8 thalamus (TH), 9 hip-
pocampus (HIP), 10 lateral tem-
poral lobe (LTL), 11 cerebellum.
c MNI PET template, single-
subject MNI MRI template and
merged template with template
ROI
Table 5 Subject characteristics of NL and AD in the FDG-PET validation study
Subjects NL AD
N 34 15
Age (years) 54 (19) [21–80] 72 (3) [65–77]
Gender (%F) 69% 65%
MMSE 29.4 (2.6) [28–30] 23.6 (2.9) [17–27]
MRglc μmol/100 g/min Automated ROIs Manual ROIs PVC manual ROIs Automated ROIs Manual ROIs PVC manual ROIs
IP 46.7 (7.7) 42.7 (6.8) 47.1 (7.1) 21.0 (4.4) 19.2 (4.1) 21.7 (4.6)
MFG 49.7 (9.3) 44.1 (7.9) 48.1 (8.3) 24.0 (5.3) 22.1 (4.5) 25.0 (5.2)
PCC 48.1 (8.7) 47.3 (8.1) 51.1 (8.2) 22.4 (4.2) 23.0 (5.1) 26.4 (5.6)
STP 40.7 (5.9) 38.4 (5.6) 42.1 (5.6) 20.4 (4.2) 20.1 (3.5) 22.7 (4.0)
Values are mean (SD) [range].
PVC Partial volume correction, IP inferior parietal lobe, MFG middle frontal gyrus, PCC posterior cingulate cortex, STG superior temporal gyrus
2178 Eur J Nucl Med Mol Imaging (2008) 35:2169–2181Frequency-Spoiled Gradient Recalled Acquisition in the
Steady State (SPGR) pulse sequence, 124 contiguous
coronal slices, 1.3 mm thick, TR=35 ms, TE=9 ms, flip
angle 60°, FOV=18 cm, 1 excitation, 256×128 matrix].
Within 3 months of the MRI, an FDG-PET scan was
performed at Brookhaven National Laboratories (BNL,
Upton, NY, USA) using 2-[18F]fluoro-2-deoxy-D-glucose
(FDG) as the tracer on an ECAT EXACT HR+ scanner
(Siemens, Knoxville, TN, USA; 3.6 mm in-plane FWHM,
2.46 mm slice thickness, 155 mm axial FOV). Subjects
received 3–5 mCi of FDG intravenously, while lying supine
in a dimly lit room. PET images were obtained 35 min after
injection and acquired over 20 min. Arterial blood samples
were drawn at standard intervals throughout the study, and
the absolute CMRglc measures (µmol/100 g/min) were
calculated using Sokoloff’s model with standard kinetic
constants [15, 16]. Data were reconstructed using filtered
back-projection (Fourier rebinning/2D back-projection,
Hanning filter with a frequency cutoff of 0.5 cycles/pixel)
and corrected for attenuation using 68 Ga/68Ge transmis-
sion scans, scatter, and radioactive decay. All the AD
patients (n=15) received FDG and PIB scans at University
of Turku, Finland. The scan information can be found in the
paper.
Results The anatomical precision and sampling accuracy of
the technique was verified on the co-registered MRI and
FDG-PET scans from the whole data set of 49 subjects.
First, we examined the anatomical fit of the automatic ROIs
on MRI by visual inspection of all the scans and all regions.
The automated ROIs fit within each anatomic region in all
the NL and MCI cases (Fig. 2). For AD, several ROIs were
displaced, but none of the ROIs were displaced by more
than 4 pixels (4 mm), which was under the approximate
resolution of the PET camera. (i.e., real resolution>4 mm
FWHM).
Figure 7
Second, for FDG, we examined the sampling accuracy
of the automated ROIs with respect to the gold-standard
manual ROI technique with 34 NL and 15 AD subjects. For
PIB, the validation was only conducted on AD subjects.
Manual ROIs were drawn on all the MRI of all subjects for
four regions (i.e., IP, MFG, STG, and PCC) based on same
boundary definition used for the automated ROIs. A two-
compartment partial volume (atrophy) correction was
applied to the manual ROIs [17]. Regional MRglc (μmol/
100 g/min) was measured from both the manual and the
automated ROIs for all subjects, and hemispheric MRglc
means computed. Intra-class correlation coefficients (ICC)
and Pearson’s correlation coefficients (r) were used to
compare the manual to the automated ROI MRglc
sampling.
The results for the manual and automated ROI data were
highly consistent for all ROIs. There were no significant
differences between the Template ROI and manual ROI for
either FDG (see Table 1) or PIB (see Table 2). Both before
a n da f t e ra t r o p h yc o r r e c t i o nf o rb o t hF D Ga n dP I B ,
excellent correlations were found between the sampling
methods. For the MRglc data, after atrophy correction, the
Fig. 7 Automatic ROIs shown
on a 72-year-old, female, normal
control subject. (GDS 2, MMSE
30.) The first row is MRI, and
the second row is co-registered
FDG-PET. ROIs include MFG,
PF, PCC, IP, STG, OL, AP, T,
and HIP
Table 6 Comparison of manual and automatic template ROIs in the
PIB-PET validation study
PIB DVR
(n=15)
Automated
ROIs
Manual
ROIs
PVC manual
ROIs
IP 1.90 (0.52) 1.89 (0.46) 2.13 (0.52)
MFG 2.00 (0.52) 1.89 (0.45) 2.15 (0.50)
PCC 2.03 (0.56) 2.03 (0.62) 2.32 (0.68)
STP 1.78 (0.40) 1.81 (0.37) 1.96 (0.40)
Values are mean (SD) [range].
PVC Partial volume correction, IP inferior parietal lobe, MFG middle
frontal gyrus, PCC posterior cingulate cortex, STG superior temporal gyrus
Eur J Nucl Med Mol Imaging (2008) 35:2169–2181 2179ICCs ranged from 0.90 superior temporal gyrus (STG) to
0.95 inferior parietal lobule (IP; p’s<.001), with r’s ranging
from 0.91 (STG) to 0.98 (IP; p’s<.001). For PIB data, after
atrophy correction, the ICCs ranged between 0.92 (STG) to
0.99 (IP; p’s<.001), and the r’s ranged between 0.93 (STG)
to 0.99 (PCC; p’s<.001).
Conclusions We demonstrate an automated technique that
enables one to regionally sample individual brain PET
scans with high anatomical precision without requiring an
MRI scan for reference or spatial normalization purposes.
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